New Medications for Neuropsychiatric Disorders

Harika M Reddy; Joshua S Poole; Gerald A Maguire; Stephen M Stahl

doi:10.1016/j.psc.2020.02.008

New Medications for Neuropsychiatric Disorders

Psychiatr Clin North Am. 2020 Jun;43(2):399-413. doi: 10.1016/j.psc.2020.02.008. Epub 2020 Apr 8.

Authors

Harika M Reddy¹, Joshua S Poole², Gerald A Maguire², Stephen M Stahl³

Affiliations

¹ Department of Psychiatry and Neuroscience, University of California Riverside School of Medicine, 14350-1 Meridian Parkway, Riverside, CA 92518, USA. Electronic address: harika.reddy@medsch.ucr.edu.
² Department of Psychiatry and Neuroscience, University of California Riverside School of Medicine, 14350-1 Meridian Parkway, Riverside, CA 92518, USA.
³ Department of Psychiatry and Neuroscience, University of California Riverside School of Medicine, 14350-1 Meridian Parkway, Riverside, CA 92518, USA; Neuroscience Education Institute, 1917 Palomar Oaks Way, Suite 200, Carlsbad, CA 92008, USA; Department of Psychiatry, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA.

PMID: 32439029
DOI: 10.1016/j.psc.2020.02.008

Abstract

This article seeks to summarize the mechanisms of action, clinical trials, and FDA approval status of several psychiatric medications that are either newly available or in the FDA approval process. This article highlights medications that demonstrate novel mechanisms of action, examines nonpsychiatric medications that are being used to augment existing psychiatric treatments, and elucidates treatments for illnesses that have not previously received FDA indications.

Keywords: Dementia; Depression; Eating; Insomnia; Schizophrenia; Sexual desire; Stuttering; Tourette’s.

Publication types

Review

MeSH terms

Antidepressive Agents / therapeutic use*
Antipsychotic Agents / therapeutic use*
Humans
Mental Disorders / drug therapy*

Substances

Antidepressive Agents
Antipsychotic Agents